Skip to content

Lunai Bioworks Inc.: 10-Q filed 2023-05-12

What Lunai Bioworks Inc. reported in its quarterly report filed 2023-05-12 (fiscal Q3 2023): 42 published measures, 114 facts as tagged in accession 0001731122-23-000898.

This filing

Form
10-Q (quarterly report)
Filed
2023-05-12
Fiscal period
fiscal Q3 2023
Accession
0001731122-23-000898 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lunai Bioworks Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-03-3178,730,729USD
At 2022-06-3084,632,663USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-03-3112,602,576USD
At 2022-06-3012,013,815USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-03-3166,128,153USD
At 2022-12-3166,899,356USD
At 2022-09-3070,324,842USD
At 2022-06-3072,618,848USD
At 2022-03-31161,242,697USD
At 2021-12-31165,619,463USD
At 2021-09-30166,974,952USD
At 2021-06-30174,662,939USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-03-312,948,042USD
At 2022-06-309,172,142USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-01-01 to 2023-03-31-4,328,296USD90
2022-07-01 to 2023-03-31-16,485,804USD274
2022-01-01 to 2022-03-31-6,201,465USD90
2021-07-01 to 2022-03-31-23,196,375USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-07-01 to 2023-03-31-9,512,937USD274
2021-07-01 to 2022-03-31-12,681,849USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2022-07-01 to 2023-03-3123,633USD274
2021-07-01 to 2022-03-315,156USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-07-01 to 2023-03-313,267,008USD274
2021-07-01 to 2022-03-313,180,274USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2022-07-01 to 2023-03-31-23,633USD274
2021-07-01 to 2022-03-31-5,156USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-03-31-220,831,001USD
At 2022-06-30-204,345,197USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2021-07-01 to 2022-03-3134USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-03-31529,254USD
At 2022-06-30586,536USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-03-311,076,203USD90
2022-07-01 to 2023-03-312,922,166USD274
2022-01-01 to 2022-03-31577,676USD90
2021-07-01 to 2022-03-315,348,943USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-03-31-4,063,436USD90
2022-07-01 to 2023-03-31-15,621,918USD274
2022-01-01 to 2022-03-31-4,034,556USD90
2021-07-01 to 2022-03-31-17,870,020USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-03-313,926,925USD
At 2022-06-309,565,138USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-01-01 to 2023-03-31122,289USD90
2022-07-01 to 2023-03-31310,766USD274
2022-01-01 to 2022-03-3195,206USD90
2021-07-01 to 2022-03-31278,327USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-03-3111,773,363USD
At 2022-06-306,450,968USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2023-03-3111,640,000USD
At 2022-06-3011,640,000USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2023-03-3141,095USD
At 2022-06-3044,268USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-01-01 to 2023-03-314,063,436USD90
2022-07-01 to 2023-03-3115,621,918USD274
2022-01-01 to 2022-03-314,034,556USD90
2021-07-01 to 2022-03-3117,870,020USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-01-01 to 2023-03-31239,137USD90
2022-07-01 to 2023-03-313,170,471USD274
2022-01-01 to 2022-03-311,212,380USD90
2021-07-01 to 2022-03-316,605,038USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-03-3157,983,591shares
At 2022-06-3053,007,082shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-03-31286,985,739USD
At 2022-06-30276,989,179USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2023-03-31-32,385USD
At 2022-06-30-30,436USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-03-31963,869USD
At 2022-06-301,157,086USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2023-03-31967,647USD
At 2022-06-30944,014USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-03-31438,393USD
At 2022-06-30357,478USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2023-03-310USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-03-3174,274,550USD
At 2022-06-3074,480,989USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-03-31593,728USD
At 2022-06-301,031,462USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-03-31978,883USD
At 2022-06-30392,996USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-01-01 to 2023-03-31-4,328,296USD90
2022-10-01 to 2022-12-31-4,457,748USD92
2022-07-01 to 2022-09-30-7,699,760USD92
2022-01-01 to 2022-03-31-6,201,465USD90
2021-10-01 to 2021-12-31-6,582,941USD92
2021-07-01 to 2021-09-30-10,411,969USD92

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2023-01-01 to 2023-03-31-4,330,406USD90
2022-07-01 to 2023-03-31-16,487,753USD274
2022-01-01 to 2022-03-31-6,204,142USD90
2021-07-01 to 2022-03-31-23,207,035USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-01-01 to 2023-03-313,796,057USD90
2022-07-01 to 2023-03-3112,365,960USD274
2022-01-01 to 2022-03-312,790,456USD90
2021-07-01 to 2022-03-3111,169,724USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-01-01 to 2023-03-3126,662USD90
2022-07-01 to 2023-03-3180,915USD274
2022-01-01 to 2022-03-3127,990USD90
2021-07-01 to 2022-03-3183,787USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2023-01-01 to 2023-03-3128,242USD90
2022-07-01 to 2023-03-3185,487USD274
2022-01-01 to 2022-03-3131,720USD90
2021-07-01 to 2022-03-3195,258USD274

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2023-01-01 to 2023-03-311,580USD90
2022-07-01 to 2023-03-314,572USD274
2022-01-01 to 2022-03-313,730USD90
2021-07-01 to 2022-03-3111,471USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-01-01 to 2023-03-31-264,860USD90
2022-07-01 to 2023-03-31-863,886USD274
2022-01-01 to 2022-03-31-2,166,909USD90
2021-07-01 to 2022-03-31-5,326,321USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2022-07-01 to 2023-03-3143,627USD274
2021-07-01 to 2022-03-3155,880USD274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2021-07-01 to 2022-03-3134USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2022-05-01 to 2022-05-17299,178USD17

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2022-07-01 to 2023-03-313,069,487USD274
2021-07-01 to 2022-03-31166,458USD274

Inspect the source

Entity
Lunai Bioworks Inc. / CIK 0001527728
Captured
2026-09-19T11:18:43.497Z
SEC response SHA-256
ac98dc0ce9d3f6a81ccca9ca1f946e5772f94eabe3529dac2d726fef17abed57

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001527728.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))